Background:Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular *** sought to determine whether alirocumab,a human monoclonal antibody to proprotein convertase subtil...
详细信息
Background:Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular *** sought to determine whether alirocumab,a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9(PCSK9),would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
暂无评论